



Oramed Pharmaceuticals Inc.
142 W. 57th St.
New York, NY
Phone: 1 844 9 ORAMED
www.oramed.com

COMPANY OVERVIEW

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP), with its breakthrough platform technology, allows for the oral delivery of drugs and vaccines that are presently available only via injection. Oramed's pipeline is currently focused on diabetes and has potential for a variety of additional treatment indications to address markets worth billions of dollars. Millions of diabetics inject insulin today and wish for an oral dosage. Based on clinical trials to date, Oramed's lead product, oral insulin, has health benefits compared to injected insulin because oral delivery mimics the body's natural processes. The Company has a robust patent portfolio covering oral delivery, methods of proteins, insulin and GLP-1. Oramed is led by a management team, directors and scientific advisors who are recognized as leaders in their field. Oramed signed an investment and licensing deal in China valued at \$50M plus 10% royalties on sales in the world's largest diabetes market. Over \$30M in payments have been received by Oramed from this agreement to date.

EQUITY OVERVIEW

(as of 2/1/2019)

Nasdaq/TASE: ORMP

Price: \$3.36

Market Cap: \$58.391M

52 Week Range: \$2.97-\$9.24

Avg. Daily Volume (90 day): 32,272

Shares Outstanding: 17.4 M

Cash & Investments: \$46.8 M (as of 8/31/18)

ANALYST COVERAGE

- H.C. Wainwright & Co.
- Aegis Capital
- FBR & Co.
- Zacks
- Frost & Sullivan

BETTER WAY TO TREAT DIABETES

**1 in 11 adults
on the planet has diabetes**

**1 healthcare
in 8
is spent on diabetes**

**every
6 SECONDS
1 adult dies
from diabetes
4M deaths in 2017**

INVESTMENT HIGHLIGHTS

Platform Technology Delivers Injectable Drugs & Vaccines Orally

Oramed's unique platform technology is a breakthrough in medical science that enables small proteins to travel through the gastrointestinal tract, via the liver, and into the bloodstream. This method of protein passage through the digestive system is more natural and should therefore eliminate the many side effects of delivery via needle directly into the bloodstream. Oramed believes that oral administration of current injection-only therapies for conditions including diabetes, offers clear benefits including fewer side effects and greater comfort for patients, which will result in increased patient compliance.

Addressing \$70 Billion Market with Oral Formulations

Roughly \$70 billion worth of drugs and vaccines are currently delivered via injections. This includes the diabetes market where \$24 billion of insulin and \$6 billion of GLP-1 analogs, a drug used to treat diabetes, were sold globally in 2017. \$33 billion worth of vaccines were sold in 2014. Interferon, which is used in the treatment of a number of diseases, was a \$10 billion global market in 2015. Oramed has signed a \$50M license agreement with HTIT, including 10% royalties on net sales in China.

Oral Treatment has the potential to Curb Progression of Type 2 Diabetes

ORMD-0801 has the potential to create a new paradigm in the treatment of type 2 diabetes by orally delivering insulin at an earlier stage of treatment. Earlier treatment, in this case by lowering nighttime glucose, can potentially slow disease progression and delay late-stage complications. Oramed recently concluded a successful Phase IIb study of ORMD-0801 which met its primary endpoints and showed that the drug reduced nighttime glucose levels. The FDA gave clear guidance to Oramed that the regulatory pathway for ORMD-0801 would be a Biologics License Application (BLA), which grants a full 12 years of marketing exclusivity for the oral insulin, if approved. Oramed is over halfway through recruitment in a 90-day HbA1c study of ORMD-0801, a prerequisite for Phase III.

Eliminating Mealtime Injections in Type 1 Diabetes

Oramed successfully concluded a Phase IIa trial of ORMD-0801 which showed Oramed's pill can potentially replace mealtime insulin injections for type 1 diabetics. Data showed blood glucose levels were lower compared to the control group. Oramed seeks to replace mealtime injections because it believes that benefits of oral ORMD-0801 include reducing multiple daily use of needles and better regulation of blood sugars.

Oral GLP-1 Analog to Stimulate Insulin Production in Type 2 Diabetes

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. It is beneficial to type 2 diabetic patients in several ways including promoting weight loss and decreased blood sugar. GLP-1 analogs are currently available only via injection. Oramed's ORMD-0901, an oral GLP-1 analog, is expected to enter an FDA Phase II multi-center study in the U.S. in 2019.